Raised serum concentrations of pancreatic enzymes in cigarette smokers

M A DUBICK, C N CONTEAS, H T BILLY, A P N MAJUMDAR, AND M C GEOKAS

From the Enzymology Research Laboratory, Department of Medicine, Veterans Administration Medical Center, Martinez, CA, and Departments of Medicine and Biological Chemistry, University of California, Davis, CA, USA

SUMMARY Circulating concentrations of digestive enzymes, certain lysosomal hydrolases and protease inhibitors were measured in 19 heavy smokers and 13 non-smokers before (basal) and at 15, 30, and 60 minutes after a single intravenous injection of secretin (75 CU). In smokers, basal serum amylase and immunoreactive pancreatic elastase 2 (IRE2) concentrations were about 100% and 25% higher respectively, than in the non-smokers, whereas, no differences were observed in basal immunoreactive cationic trypsinogen (IRCT) concentrations and in acid phosphatase and β-glucuronidase activities between the two groups. Furthermore, a single injection of secretin to cigarette smokers significantly increased serum amylase, IRCT and IRE2 by 155%, 200%, and 100%, respectively when compared with their corresponding basal levels. No such increment was observed in the non-smokers. In addition, there were no significant differences in serum trypsin or elastase inhibitory capacity or immunoreactive α1-protease inhibitor and α2-macroglobulin levels between smokers and non-smokers. The levels and inhibitory capacity of these protease inhibitors was also not affected by secretin injection. These data suggest that cigarette smoking enhances the responsiveness of the exocrine pancreas to a physiological stimulus such as secretin, with resultant substantial increase in the concentrations of pancreatic hydrolases in blood.

Cigarette smoking is a well recognised risk factor in the aetiology of pulmonary emphysema,1,2 coronary artery disease and aortic aneurysms,3,4 and has been linked to the development of pancreatitis5 and pancreatic carcinoma.6 Although the mechanism(s) that relate smoking to these diseases are not well understood, enzymes with elastase-like activity have been implicated in the pathogenesis of emphysema and aortic aneurysms.6,7,8

Accumulating evidence suggests that nicotine affects exocrine pancreatic secretion. Several investigators9,10,11,15 have shown that cigarette smoking in man or infusion of nicotine in experimental animals inhibits both basal and secretin mediated stimulation of pancreatic fluid and bicarbonate secretion with no apparent change in protein output. In contrast, Ballin, et al.16 have observed raised serum concentrations of amylase, cationic trypsinogen and pancreatic secretory trypsin inhibitor after secretin injection in cigarette smokers. We have recently shown that exposure of isolated rat pancreatic acini to nicotine greatly stimulates the secretion of pre-formed exportable hydrolases and newly synthesised proteins.17,18 This observation indicates that nicotine exerts a direct effect on the exocrine pancreatic cell.

In addition to nicotine, tobacco smoke also contains other cytotoxic agents which may affect exocrine pancreatic function. For example, recent data from this laboratory demonstrate that acetaldehyde, the primary metabolite of ethanol and a constituent of tobacco smoke19 inhibits cholecystokinin induced amylase release from isolated pancreatic acini and the binding of cholecystokinin to acinar membranes.20

The present study was undertaken to further investigate alterations in the responsiveness of the exocrine pancreas to secretin stimulation and its effect on the protease antiprotease balance in heavy cigarette smokers. The circulating levels of digestive enzymes, certain lysosomal hydrolases and protease inhibitors were measured in serum from non-

Address for correspondence: Dr Michael Dubick, Department of Medicine (15IF), VA Medical Center, Martinez, CA 94553, USA.

Received for publication 3 July 1986.
smokers and heavy smokers of different ages before and after a single iv injection of secretin. Furthermore, efforts were also made to relate these findings to the history of alcohol consumption in the subjects.

Methods

SUBJECTS

Nineteen smokers (16 men, three women) were recruited from the patients and staff of the VA Medical Center (Martinez, CA). Except for one subject, all had smoked for a minimum of eight years with a smoking history of 65-7±8-1 pack years (mean±SEM). The majority smoked at least two packs of cigarettes/day. The subjects ranged in age from 30-68 years (52-2±2-5) and 13 of them consumed significant amounts of alcohol regularly. Although coffee consumption was not controlled for this study, Andriulli et al. found that coffee intake did not affect serum trypsin concentrations after secretin injection. Nine young, healthy, volunteer students (four men, five women), ranging in age from 25-35 years, served as controls with no history of smoking or alcohol abuse. In addition, four male non-smokers, ranging in age from 53-76 years served as controls to the more aged smokers. Subjects were fasted overnight before testing and the smokers were allowed to smoke up to the test period.

BLOOD SAMPLES AND SECRETIN INJECTION

Venous blood was obtained before and 15, 30, and 60 minutes after a single rapid injection (iv over 1 min) of 75 CU of secretin (KabiVitrum CB Laboratories, Stockholm, Sweden). Blood was allowed to coagulate on ice for at least two hours and serum was isolated by centrifugation (2000 g, 15 min). Serum was stored at −80°C until assayed.

ENZYMES AND SUBSTRATES

Bovine trypsin (EC 3.4.21.11) and porcine pancreatic elastase (EC 3.4.21.11) were obtained from Worthington Biochemical Corp, Freehold, NJ. Porcine pancreatic amylase was a product of Calbiochem-Behring (LaJolla, CA). Tosyl-arginine-methyl ester (TAME) and succinyl-tri-alanine-p-nitroanilide (SLAPNA) were from Sigma Chemical Co (St Louis, MO). Agarose was purchased from Biorad Laboratories (Richmond, CA). All reagents used for biochemical measurements were of analytical grade or the purest commercially available.

ENZYME ASSAYS

Amylase

Amylase concentrations in serum were determined by the method of Jung using procion yellow coupled to starch as substrate.

Hydrolases

β-glucuronidase and acid phosphatase activity was determined colorimetrically according to Sigma Technical Bulletins 325 and 104, respectively. β-glucuronidase activity was expressed as a microgram phenolphthalein liberated/h/ml. Acid phosphatase activity was expressed as μmoles p-nitrophenol liberated/h/ml.

Gamma-glutamyl transpeptidase

Gamma-glutamyl transpeptidase activity was assayed by the colorimetric procedure outlined in Sigma Technical Bulletin 545.

Radioimmunoassays

Serum immunoreactive cationic trypsinogen (IRCT) and immunoreactive elastase 2 (IRE2) concentrations were determined by radioimmunoassay as previously described except that 0-12% normal rabbit immunoglobulin was removed from the assay buffer. After a four day incubation at 4°C, the antigen-antibody complex was precipitated with goat-antirabbit immunoglobulin bound to agarose. A dilution of 1:100000 of specific antiserum to both enzymes was used. Three appropriate dilutions were analysed in duplicate and results were expressed as ng/ml of cationic trypsinogen (o) or elastase 2 by comparison with purified human cationic trypsin or elastase 2 as standards.

Other assays

The concentrations of immunoreactive α1-protease inhibitor (α1-PI) and α2-macroglobulin (α2-M) in serum were determined by the rocket immunoelectrophoresis procedure of Laurell and McKay.

Trypsin inhibitory capacity was determined by incubation of a known amount of purified bovine trypsin with serum and measuring the inhibition of trypsin hydrolysis of TAME. Inhibitory capacity was assessed from the difference in slope in the absence (water blank) and presence of serum. Elastase inhibitory capacity was measured similarly by inhibition of the hydrolysis of SLAPNA after incubation of purified pancreatic elastase with serum.

Serum albumin concentrations were determined by the bromocresol green dye-binding assay (Sigma Chemical Co). Methemalbumin was assayed by the method of Walberg et al. and results were expressed as milligrams haematin/100 ml.

Statistical analysis

Results were analysed by Student’s t test for comparison of the means between the smokers and non-smokers and basal and stimulated values within groups.
Results

It was observed that both the basal and secretin stimulated levels of amylase and immunoreactive cationic trypsin(ogen) and elastase 2 were similar in both the young and aged non-smokers. Consequently, all non-smoking subjects were combined into a single group.

In smokers basal serum amylase and immunoreactive elastase 2 concentrations were found to be 100% and 24% higher, respectively, than in the non-smokers (Figure). Serum IRCT concentrations between the two groups were, however, the same (Figure). These observations remained unchanged when the smokers were subdivided according to age (>50 years old) or their drinking habits (those who consumed alcohol regularly).

A single injection of secretin increased serum amylase concentrations an additional 2-6-fold in all smokers, and 3-2-fold in those who smoked and drank alcohol (smoking+drinking group) (Figure). Serum enzyme concentrations in the smokers group were higher at all time periods in comparison with controls. Therefore, only the maximum stimulated levels (at 15 min) are reported. Serum amylase concentrations in the non-smoking controls were unaffected by the hormone (Figure). In addition, serum IRCT and IRE2 levels were 3-4 and 2-1-fold higher, respectively, after secretin injection, than their corresponding basal levels (Figure). Again the greatest stimulation in circulating levels of pancreatic proteases was observed in the 'smoking+drinking' group. In general data from individual smokers showed that the secretin stimulated increase of amylase was accompanied by raised serum cationic trypsin(ogen) and elastase 2. None of these changes were observed in the non-smoker control subjects (Figure). We wish to emphasise that whereas trypsinogen and elastase 2 are pancreas specific, the origin of the increased concentrations of amylase cannot be ascertained because assay for amylase isoenzymes was not performed.

As shown in Table 1, the basal levels of immunoreactive $\alpha_1$-protease inhibitor ($\alpha_1$-PI) and $\alpha_2$-macroglobulin ($\alpha_2$-M) in any of the categories of smokers were the same or slightly higher in comparison with the controls. Similar results were observed

![Figure](http://gut.bmj.com/)

Figure  Concentrations of amylase, cationic trypsin(ogen) and elastase 2 in serum. Data expressed as mean ± SE of 10-19 samples. Open bar, non-smokers; closed bar, all smokers; hatched bar, smokers over 50 years old; stippled bar, smokers and drinkers. Means with different letters are significantly different ($p<0.05$).

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Serum protease-inhibitor levels and activity*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Non-smokers $n=13$</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------</td>
</tr>
<tr>
<td>$\alpha_1$-PI (mg/100 ml)</td>
<td>317 ± 14</td>
</tr>
<tr>
<td>$\alpha_2$-M (mg/100 ml)</td>
<td>194 ± 13</td>
</tr>
<tr>
<td>TIC$^s$ (% inhib/10μl)</td>
<td>39.2 ± 2.1</td>
</tr>
<tr>
<td>ELC$^s$ (% inhib/20μl)</td>
<td>73.1 ± 2.9</td>
</tr>
</tbody>
</table>

*Data expressed as mean ± SE; $\alpha_1$-Protease inhibitor; $\alpha_2$-Macroglobulin; $^s$Trypsin-inhibitory capacity; $^s$Elastase-inhibitory capacity.
Circulating enzymes in smokers

with respect to assessment of elastase-inhibitory capacity of α₁-PI (Table 1). In most cases, however, trypsin inhibitory capacity of α₁-PI was slightly higher in the non-smokers, though the differences were not statistically significant. In addition none of these parameters were significantly affected by secretin in any group. Thus, these data translate into a two to three fold increase in the protease-to-protease inhibitor ratio in serum from heavy smokers after secretin administration (Figure, Table 1).

Furthermore, no significant differences were noted in circulating concentrations of lysosomal hydrolases between the smokers and non-smokers during the course of the study (Table 2). Acid phosphatase and β-glucuronidase activity was within normal limits in all but two smokers. Again these two individuals were heavy drinkers as well. γ-glutamyl transpeptidase activity was, however, higher in all groups of smokers than in controls (Table 2). Raised γ-glutamyl transpeptidase activity was particularly pronounced in individuals who were also heavy drinkers.

Smokers also had lower serum albumin concentrations compared with non-smokers (Table 2), and no methemalbumin was detected in serum from smokers either before or after secretin administration.

Discussion

The exocrine pancreas is one of the most metabolically active organs in the body, as evidenced by its high rate of protein synthesis. Its major function is to secrete into the gut, on demand, large quantities of bicarbonate, water and digestive enzymes. Under normal conditions, pancreatic enzymes enter the duodenum via the pancreatic duct, with a small fraction being directly secreted into the blood. In serum from normal healthy adults, fasting levels of immunoreactive trypsinogen and elastase 2 averaged 26 ng/ml and 71 ng/ml, respectively, with no significant variation between adults of various ages. This observation is consistent with data obtained from the non-smokers in this study. In contrast, it is known that pancreatic inflammation results in a profound rise in circulating concentrations of pancreatic hydrolases.

Although the smokers used in the present study were apparently healthy, their basal circulating concentrations of amylase and immunoreactive elastase 2 were found to be significantly higher than in the non-smoking controls. Furthermore, a single injection of secretin produced a profound rise in serum amylase, immunoreactive cationic trypsinogen and elastase 2. This effect was not seen in the non-smokers. Baldini et al. and Andriulli et al. have also observed a rise in serum immunoreactive trypsin concentrations in smokers after secretin injection. Whether these results are because of increased synthesis and/or enhanced secretion of enzymes, is at present unknown. We have recently observed, however, that in rats, administration of acetaldehyde, the primary metabolite of ethanol and a constituent of tobacco smoke, significantly reduced the amylase and trypsinogen content of the pancreas and increased serum amylase concentrations. Further, it was observed that in dispersed pancreatic acini from acetaldehyde treated rats, basal secretion of preformed exportable hydrolases, amylase, trypsinogen and chymotrypsinogen was increased 40–50% over control levels and nicotine-induced enzyme release was enhanced. These data suggest that acetaldehyde treatment enhances pancreatic enzyme secretion. Since similar results have been observed after nicotine infusion in rats (Majumdar, Dubick, Vesenka and Geokas – unpublished observations), it appears that heavy cigarette smoking may result in an accelerated secretion of pancreatic enzymes.

Because pancreatic secretion into the duodenum was, however, not measured in this study, the precise mechanism(s) for the increased serum enzyme concentrations observed remain unknown. Previous studies have shown that nicotine infusion or cigarette smoking alter interdigestive pancreatic exocrine secretion into the duodenum. As bile secretion into the duodenum is also affected by cigarette smoking, it is possible that smoking may induce an 'exit block' at the level of the sphincter of Oddi. At present we are unaware of any studies on the direct effects of nicotine or cigarette smoking on sphincter of Oddi motility.

Table 2 Serum albumin lysosomal hydrolases and GGTP* activity†

<table>
<thead>
<tr>
<th>Non-smokers</th>
<th>All</th>
<th>Smokers Smokers over 50 years old</th>
<th>Smoke + drink</th>
</tr>
</thead>
<tbody>
<tr>
<td>n = 13</td>
<td>n = 19</td>
<td>n = 10</td>
<td>n = 13</td>
</tr>
<tr>
<td>Albumin (g/dl)</td>
<td>4.5 ± 0.1</td>
<td>3.7 ± 0.2‡</td>
<td>3.9 ± 0.2‡</td>
</tr>
<tr>
<td>Acid phosphatase (umol p-nitrophenol/h/ml)</td>
<td>0.27 ± 0.02</td>
<td>0.34 ± 0.03</td>
<td>0.37 ± 0.05</td>
</tr>
<tr>
<td>β-Glucuronidase (µg phenolphthalein/h/ml)</td>
<td>21.5 ± 2.8</td>
<td>25.1 ± 3.3</td>
<td>19.2 ± 2.2</td>
</tr>
<tr>
<td>GGTP (units/ml)</td>
<td>14.1 ± 1.8</td>
<td>32.9 ± 7.8‡</td>
<td>42.2 ± 12.5</td>
</tr>
</tbody>
</table>

* Gamma glutamyl transpeptidase; † Data expressed as mean ± SE; ‡ p<0.05.
It also appears that the effect of secretin on pancreatic enzyme secretion is multifactorial. After secretin infusion in six patients, Gullo et al. concluded that secretin induced pancreatic enzyme secretion through a direct action on the acinar cells, while Carr-Locke et al. observed that secretin infusion selectively relaxed the pancreatic duct sphincter without any effect on the common bile duct or bile duct sphincters. DiMagno et al. also observed that secretin dilated the pancreatic duct and decreased the flow of pancreatic juice into the duodenum. A differential effect of secretin on duct and sphincter pressures could also result in an 'exit block' and may explain, in part, the observed effects of secretin on serum amylase and lipase in patients with biliary and pancreatic disease. Further studies in this area are clearly indicated.

In addition, the present study showed that the secretin stimulated serum levels of pancreatic hydrolases tended to be only slightly higher in the subjects who smoked and imbibed alcohol regularly, as compared with the cigarette smokers group as a whole. Although numerous studies have shown that ethanol affects exocrine pancreatic function both in vitro and in vivo, the present data do not support an additive effect of cigarette smoking and ethanol consumption on exocrine pancreatic secretion.

Our study also shows that trypsin and elastase inhibitory capacity and circulating levels of $\alpha_1$-PI and $\alpha_2$-M were not significantly different between smokers and non-smokers. Carp and Janoff found that fresh cigarette smoke could suppress elastase-inhibitory capacity in vitro and Beatty et al. reported the presence of oxidised $\alpha_1$-PI in serum from cigarette smokers. Other investigators, however, did not observe decreased protease inhibitory capacity in cigarette smokers. Although protease inhibitory capacity was not significantly compromised in the smokers of this study, the data show an increase in the protease to inhibitor ratio in serum from cigarette smokers. This condition has been hypothesised as a major factor in the pathogenesis of pulmonary emphysema and aortic aneurysms.

Thus, the results of the present study as well as those of others indicate that secretin induces increased circulating levels of pancreatic proteases in heavy cigarette smokers, without affecting enzyme levels in non-smokers. Therefore, it is tempting to speculate that an enhanced responsiveness of the pancreas to physiological stimuli – for example, in response to food intake resulting in hormonal secretion, may result in episodic increases in circulating protease levels in chronic cigarette smokers. With the increased protease/inhibitor ratio observed in serum in our present study, and our recent detection of immunoreactive pancreatic cationic trypsinogen and elastase 2 in human abdominal aortic aneurysms, these studies suggest that circulating pancreatic proteolytic enzymes could be operative, at least in part, in the initiation of pulmonary emphysema and aortic aneurysms, diseases often associated with heavy cigarette smoking. Work is now in progress in order to investigate this hypothesis.

H T Billy is the recipient of a student fellowship from the American Heart Association, California Affiliate.

This work was supported by the Medical Research Service of the Veterans’ Administration and by a Grant-in-Aid from the American Heart Association, California Affiliate and with funds contributed by the American Heart Association, Santa Clara County Chapter.

References

35 Bell JS, Go VLW, DiMagno EP. Cigarette smoking normalizes the interdigestive pancreatic exocrine and biliary secretion of heavy smokers. Gastroenterology 1981; 80: 1108.